Thomasville National Bank Sells 1,863 Shares of Johnson & Johnson $JNJ

Key Points

• Thomasville National Bank reduced its holdings in Johnson & Johnson by 9.6%, now owning 17,465 shares valued at approximately $2.67 million.
• Major investors have shown varying activity with Johnson & Johnson, with Assenagon Asset Management increasing its position by 159.6% and acquiring over 2.5 million shares during the same quarter.
• Johnson & Johnson announced a quarterly dividend of $1.30 per share, reflecting a 3.0% yield with a payout ratio of 55.61%.

Thomasville National Bank trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 9.6% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 17,465 shares of the company's stock after selling 1,863 shares during the quarter. Thomasville National Bank's holdings in Johnson & Johnson were worth $2,668,000 as of its most recent filing with the SEC.

Other large investors have also bought and sold shares of the company. Highline Wealth Partners LLC increased its stake in Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after purchasing an additional 86 shares in the last quarter. Stone House Investment Management LLC bought a new stake in Johnson & Johnson during the 1st quarter worth approximately $47,000. 1248 Management LLC bought a new stake in Johnson & Johnson during the 1st quarter worth approximately $48,000. von Borstel & Associates Inc. bought a new stake in Johnson & Johnson during the 1st quarter worth approximately $49,000. Finally, Capital A Wealth Management LLC bought a new stake in Johnson & Johnson during the 4th quarter worth approximately $50,000. 69.55% of the stock is owned by institutional investors.

Analyst Ratings Changes

JNJ has been the subject of a number of recent research reports. UBS Group upped their price target on Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a research report on Thursday, July 17th. The Goldman Sachs Group upped their price target on Johnson & Johnson from $185.00 to $186.00 and gave the stock a "buy" rating in a research report on Friday. Citigroup upped their price target on Johnson & Johnson from $185.00 to $200.00 and gave the stock a "buy" rating in a research report on Thursday, August 21st. JPMorgan Chase & Co. upped their price target on Johnson & Johnson from $185.00 to $200.00 and gave the stock a "neutral" rating in a research report on Tuesday, September 16th. Finally, Guggenheim raised Johnson & Johnson from a "neutral" rating to a "buy" rating and upped their price target for the stock from $167.00 to $206.00 in a research report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, Johnson & Johnson presently has an average rating of "Moderate Buy" and a consensus target price of $181.40.

Johnson & Johnson Stock Up 1.3%

Shares of NYSE JNJ traded up $2.19 during midday trading on Tuesday, hitting $176.40. 3,238,731 shares of the stock traded hands, compared to its average volume of 8,915,940. The company has a market cap of $424.82 billion, a PE ratio of 18.87, a P/E/G ratio of 2.24 and a beta of 0.40. Johnson & Johnson has a one year low of $140.68 and a one year high of $181.16. The business has a 50 day moving average price of $173.14 and a two-hundred day moving average price of $161.69. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter in the prior year, the company posted $2.82 earnings per share. Johnson & Johnson's revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is 55.61%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.